Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on MRNS. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a research note on Monday, September 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Finally, TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Down 0.8 %

Shares of Marinus Pharmaceuticals stock opened at $0.53 on Friday. The company has a market capitalization of $29.45 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. The stock’s 50-day simple moving average is $0.33 and its 200-day simple moving average is $1.04. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $11.26.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Point72 DIFC Ltd bought a new stake in Marinus Pharmaceuticals during the second quarter worth approximately $28,000. AQR Capital Management LLC increased its position in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $64,000. World Investment Advisors LLC purchased a new stake in Marinus Pharmaceuticals during the 3rd quarter valued at $104,000. Finally, Squarepoint Ops LLC bought a new stake in Marinus Pharmaceuticals in the second quarter worth $206,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.